AI for Vaccine Development Market Research Report Segmented By Application (Vaccine Exploration/Preclinical, Vaccine Clinical Developments and Trials, and Vaccine Manufacturing and QC); By End User (Pharmaceutical & biotechnology companies, Contract Research Organization, and Research centers); and Region - Size, Share, Growth Analysis | Forecast (2024 2030)

Global AI for Vaccine Development Market Size (2024 - 2030):

The valuation of the global AI for Vaccine Development Market reached $11.57 billion in 2023 and is anticipated to achieve $118.65 billion by 2030, showcasing a compound annual growth rate (CAGR) of 39.45% during the forecast period spanning from 2024 to 2030.

According to the research findings, the surge in infectious diseases, extensive research and development initiatives, technological progress, and widespread integration of AI in healthcare practices by various pharmaceutical and biotechnology entities globally propel the expansion of the AI for Vaccine Development market. The market growth is attributed to the manifold advantages of AI in vaccine production, encompassing its capacity to discern vaccine targets, streamline preclinical and clinical trials, systematize data for researchers, monitor vaccine distribution, among other functionalities. The traditional complexities associated with drug discovery, characterized by prolonged timelines and substantial expenses, can potentially be mitigated by AI's simultaneous consideration of multiple factors, potentially shortening the overall testing process from years to months. AI's contribution extends to the creation of a self-learning platform incorporating real-time data and historical clinical and pharmaceutical information.

In drug design endeavors, the molecular structure of medicines plays a pivotal role. AI and machine learning algorithms leverage information engines to garner insights for developing new medication candidates or repurposing existing ones. These algorithms predict potential targets and identify the most effective ones based on factors such as opportunity, anticipated response reliability, and safety. Pharmaceutical firms employ AI to streamline and expedite the clinical development process, enabling faster drug releases to the market. AI's application extends beyond gene sequencing, addressing therapeutic efficacy prediction, adverse effects anticipation, and the management of extensive paperwork and data essential for pharmaceutical products.

Impact of COVID-19 on AI for Vaccine Development Market:

The AI for Vaccine Development Market has witnessed a substantial impact from the COVID-19 pandemic. Since 2020, both domestic and international research teams and laboratories have been actively engaged in vaccine creation efforts. Notably, China faced severe repercussions initially, prompting collaborative efforts such as Baidu's development of the AI tool LinearFold in association with Oregon State University and the University of Rochester. Leading pharmaceutical company Pfizer utilized emerging technologies, including AI, smart analytics, and automation, for the efficient delivery of a safe COVID-19 vaccine. Google's Deepmind employed AI technology to predict structures of six COVID-19-related proteins, providing valuable insights for future research and vaccine development. AI's role in drug research against COVID-19 has been instrumental, particularly in diagnostics and pharmacology. The global endeavor to apply AI for testing purposes contributes significantly to market growth.

Market Drivers for AI in Vaccine Development:

The market is expanding owing to the several benefits of AI in vaccine production, including its ability to identify vaccine targets, facilitate preclinical testing and clinical trials, organize data for researchers, track vaccine distribution, and more:

The market's expansion is fueled by the numerous benefits of AI in vaccine production, ranging from identifying vaccine targets to facilitating preclinical testing, clinical trials, data organization, and vaccine distribution tracking. Machine learning systems and computational studies enabled by AI play a crucial role in understanding virus structures, predicting immune response-supportive components, and comprehending genetic alterations of the virus over time. AI algorithms aid in preclinical testing, dosage calculations, immune response prediction, and identifying optimal sites for clinical trials. The potential of AI extends beyond vaccine production to encompass distribution, delivery, tracking, and counseling.

Market Restraints:

Challenges related to accuracy in data collection, validation, sharing, and training pose limitations to AI's growth in the vaccine development sector.

Patient privacy concerns, data security, and interoperability issues make it challenging to obtain, access, and utilize healthcare data. High infrastructure investment requirements, involving specialized workstations, servers, and connectivity, may impede market expansion. Issues such as bias, fairness, and validation difficulties associated with external data sources used in algorithm development further contribute to market restraints.

AI for Vaccine Development Market – By Application

• Vaccine Exploration/Preclinical
• Vaccine Clinical Developments and Trials
• Vaccine Manufacturing and QC

During the initial stages of drug discovery, there is often a screening process based on previous research and treatments. To identify potential therapeutic options, researchers can utilize AI to analyze vast digital repositories of data with significantly greater precision than manual processing, such as scrutinizing the characteristics of tens of thousands of pharmacological compounds. Additionally, AI can be deployed in DNA sequencing based on intricate human data, allowing physicians to conduct genetic matching and immunological response tests.

Clinical development involves testing the vaccine on diverse groups, assessing safety, and ensuring compliance with medical regulations during the regulatory review and approval process. Manufacturing and quality control (QC) are integral for preparing medications for widespread distribution. By integrating AI and sensor-based technology, companies can leverage detailed data to enhance supply chain efficiency, reducing the risk of product spoilage during distribution and mitigating demand-supply misalignments in production operations.

Each of these phases plays a pivotal role in ensuring the efficiency and safety of the developed vaccine, comprehending any adverse effects, and facilitating scalable and consistent production until the threat of the disease is sufficiently reduced. Historically, addressing emergent health issues has been hindered by the complexity, regulation, and costs associated with these stages. The advancements in AI technology have significantly expedited the process. The market is witnessing growth due to increased government funding, ongoing research projects enhancing vaccine development, and expanded business development strategies by reputable pharmaceutical firms.

AI for Vaccine Development Market – By End User

• Pharmaceutical & biotechnology companies
• Contract Research Organization
• Research centers

In 2021, Pharma and Biopharma firms spearheaded the market, contributing over 42% of total revenue. These entities played a crucial role in early-stage SARS-CoV-2 investigations during the pandemic, benefiting from their established infrastructure for vaccine research. The substantial market share can be attributed to the robust investment capabilities of pharmaceutical companies, facilitating the rapid development of the COVID-19 vaccine. Collaboration between large pharmaceutical and biotech firms is aiding in scaling up the COVID-19 vaccine manufacturing process. Research institutes are focused on conducting investigations and creating online tools for rapid vaccine development.

AI for Vaccine Development Market - By Region

• North America
• Europe
• Asia-Pacific
• Rest of the World

North America dominated the AI in vaccine development market in 2022, followed by Europe and APAC, owing to its early adoption of cutting-edge technologies. The region's expansion is attributed to factors such as increased research and development efforts, funding initiatives, the presence of key players, rising COVID-19 cases, and a sizable population base receiving the COVID-19 vaccine. Government initiatives, like the US Operation Warp Speed, have also contributed to market growth. North America benefits from a concentration of top pharmaceutical firms, including Pfizer, Abbott Laboratories, and Johnson & Johnson, along with significant R&D investments.

For companies in the AI vaccine development market, emerging markets like China, India, and the Middle East present substantial growth prospects. The demand for pharmaceuticals in these nations is expected to rise due to increased prevalence of diseases, higher income levels, and improved healthcare infrastructure. These markets are particularly appealing to businesses facing challenges in mature markets, patent expirations, and growing regulatory burdens.

AI for Vaccine Development Market - Key Players

1. Benevolent AI
2. Pfizer
3. Evaxion Biotech
4. AstraZeneca
5. Eli Lilly
6. Moderna
7. Novartis
8. Baidu
9. Exscientia
10. Roche
11. VantAI
12. Sanofi
13. Cyclica
14. PathAI
15. Atomwise
16. BioSymetrics